| Project/Area Number |
26861132
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Respiratory surgery
|
|---|
| Research Institution | Miyagi Prefectural Hospital Organization Miyagi Cancer Center |
|---|
Principal Investigator |
SUGAWARA SAYURI 地方独立行政法人宮城県立病院機構宮城県立がんセンター(研究所), がん先進治療開発研究部, 共同研究員 (10728190)
|
|---|
| Project Period (FY) |
2014-04-01 – 2016-03-31
|
| Project Status |
Completed (Fiscal Year 2015)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
Fiscal Year 2014: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | がん幹細胞 / 頭頸部癌 / レトロマー / 癌 / 扁平上皮癌 |
|---|
| Outline of Final Research Achievements |
Cancer stem cell theory applies to a number of malignant cancers including lung cancer, and specific markers to identify such stem cells remain to be elucidated. To investigate a potential contribution of CD271 in Squamous cell cancer, CD271-positive cell population was analyzed. Patient-derived xenograft (PDX) lines were successfully established. CD271+ population sorted from PDX-derived SCC showed an enhanced tumor-formation capability in highly immunodeficient NOG mice. Both of the CD271-positive and -negative cells are included in tumors generated from CD271-cell derived tumors, which suggested that the CD271+ population could undergo differentiation into CD271- one. Tumor-spheres contained more CD271+ cells than those from the normal in vitro culture condition. In in vivo tumors treated by the CDDP treatment, contained significantly more CD271+ cells, suggesting that CD271+ cells are chemo-resistant. The current findings suggested that CD271 is a novel marker for SCC stem cells.
|
